29 / 30
29
neuromyelitis optica. Ther Apher Dial
2009;13:505-8.
31. Capobianco M, Malucchi S, di Sapio A, Gilli F,
Sala A, Bottero R, et al. Variable responses to
rituximab treatment in neuromyelitis optica
(Devic's disease). Neurol Sci 2007;28:209-11.
32. Mahmood NA, Silver K, Onel K, Ko M, Javed A.
Efficacy and safety of rituximab in pediatric
neuromyelitis
optica.
J
Child
Neurol
2011;26:244-7.
33. Pellkofer HL, Krumbholz M, Berthele A,
Hemmer B, Gerdes LA, Havla J, et al. Long-term
follow-up of patients with neuromyelitis optica
after repeated therapy with rituximab.
Neurology 2011;76:1310-5.
34. Cross AH, Waubant E. MS and the B cell
controversy.
Biochim
Biophys
Acta
2011;1812:231-8.
35. Shimizu Y, Fujihara K, Kubo S, Takahashi T,
Misu T, Nakashima I, et al. Therapeutic efficacy
of interferon β-1b in Japanese patients with
optic-spinal multiple sclerosis. Tohoku J Exp
Med 2011;223:211-4.
36. Cabre P, Gonzalez-Quevedo A, Lannuzel A,
Bonnan M, Merle H, Olindo S, et al. Descriptive
epidemiology of neuromyelitis optica in the
Caribbean
basin.
Rev
Neurol
(Paris)
2009;165:676-83.